Novartis

Novartis, a multinational pharmaceutical company, is currently newsworthy for a few reasons. Firstly, it has been highlighted as a defensive stock with strong visibility in financial analysis, specifically mentioned in the BFM Business's "Good Morning Market" program. This suggests a perceived stability and reliability in the current economic climate. Secondly, and unrelated to the financial analysis, the company's relevance is underscored by the recent news that Scotland has become the first part of the UK to implement newborn screening for spinal muscular atrophy (SMA). While the articles don't explicitly state Novartis's direct involvement in the screening program, SMA treatments exist, and early detection is crucial for their effectiveness, potentially impacting the demand for such treatments. GSK's acquisition of RAPT, a food allergy drug maker, is also mentioned, though it doesn't directly involve Novartis, it highlights the dynamic nature of the pharmaceutical industry.